Linda Wu, Ph.D.

Chief Development Officer (CDO)

Over 20 years of industry experiences and a successful track record in new drug R&D, commercialization, and portfolio management, including extensive global experiences in building and leading clinical R&D teams to successfully launch innovative oncology products in China and global markets.

Former Group Medical Director in Oncology, US Medical Affairs, Senior Director and Head of Clinical Development Oncology in China, Compound Development Team Leader at Janssen, led and contributed to the approvals and launches of multiple oncology assets in China, including the unprecedented NDA conditional approval of ERLEADA® nm-CRPC in China in 2019.

PhD in Molecular Biology and Biochemistry at the University of Southern California. MS in Cancer Pharmacology at the Shanghai Institute of Materia Medica, Academia Sinica and BS from Shanghai Medical College, Fudan University.